anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Neuroinflammation reportedly plays a critical role in the pathogenesis of sepsis-associated encephalopathy (SAE). We previously reported that circulating plasma extracellular vesicles (EVs) from septic mice are proinflammatory. In the current study, we tested the role of sepsis plasma EVs in neuroinflammation.
METHODS: To track EVs in cells and tissues, HEK293T cell-derived EVs were labeled with the fluorescent dye PKH26. Cecal ligation and puncture (CLP) was conducted to model polymicrobial sepsis in mice. Plasma EVs were isolated by ultracentrifugation and their role in promoting neuronal inflammation was tested following intracerebroventricular (ICV) injection. miRNA inhibitors (anti-miR-146a, -122, -34a, and -145a) were applied to determine the effects of EV cargo miRNAs in the brain. A cytokine array was performed to profile microglia-released protein mediators. TLR7- or MyD88-knockout (KO) mice were utilized to determine the underlying mechanism of EVs-mediated neuroinflammation.
RESULTS: We observed the uptake of fluorescent PKH26-EVs inside the cell bodies of both microglia and neurons. Sepsis plasma EVs led to a dose-dependent cytokine release in cultured microglia, which was partially attenuated by miRNA inhibitors against the target miRNAs and in TLR7-KO cells. When administered via the ICV, sepsis plasma EVs resulted in a marked increase in the accumulation of innate immune cells, including monocyte and neutrophil and cytokine gene expression, in the brain. Although sepsis plasma EVs had no direct effect on cytokine production or neuronal injury in vitro, the conditioned media (CM) of microglia treated with sepsis plasma EVs induced neuronal cell death as evidenced by increased caspase-3 cleavage and Annexin-V staining. Cytokine arrays and bioinformatics analysis of the microglial CM revealed multiple cytokines/chemokines and other factors functionally linked to leukocyte chemotaxis and migration, TLR signaling, and neuronal death. Moreover, sepsis plasma EV-induced brain inflammation in vivo was significantly dependent on MyD88.
CONCLUSIONS: Circulating plasma EVs in septic mice cause a microglial proinflammatory response in vitro and a brain innate immune response in vivo, some of which are in part mediated by TLR7 in vitro and MyD88 signaling in vivo. These findings highlight the importance of circulating EVs in brain inflammation during sepsis.
BACKGROUND: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia in the world. AF increases the risk of stroke 5-fold, though the risk can be reduced with appropriate treatment. Therefore, early diagnosis is imperative but remains a global challenge. In low-and middle-income countries (LMICs), a lack of diagnostic equipment and under-resourced healthcare systems generate further barriers. The rapid development of digital technologies that are capable of diagnosing AF remotely and cost-effectively could prove beneficial for LMICs. However, evidence is lacking on what digital technologies exist and how they compare in regards to diagnostic accuracy. We aim to systematically review the diagnostic accuracy of all digital technologies capable of AF diagnosis.
METHODS: MEDLINE, Embase and Web of Science will be searched for eligible studies. Free text terms will be combined with corresponding index terms where available and searches will not be limited by language nor time of publication. Cohort or cross-sectional studies comprising adult (≥18 years) participants will be included. Only studies that use a 12-lead ECG as the reference test (comparator) and report outcomes of sensitivity, specificity, the diagnostic odds ratio (DOR) or the positive and negative predictive value (PPV and NPV) will be included (or if they provide sufficient data to calculate these outcomes). Two reviewers will independently assess articles for inclusion, extract data using a piloted tool and assess risk of bias using the QUADAS-2 tool. The feasibility of a meta-analysis will be determined by assessing heterogeneity across the studies, grouped by index device, diagnostic threshold and setting. If a meta-analysis is feasible for any index device, pooled sensitivity and specificity will be calculated using a random effect model and presented in forest plots.
DISCUSSION: The findings of our review will provide a comprehensive synthesis of the diagnostic accuracy of available digital technologies capable for diagnosing AF. Thus, this review will aid in the identification of which devices could be further trialed and implemented, particularly in a LMIC setting, to improve the early diagnosis of AF.
TRIAL REGISTRATION: Systematic review registration: PROSPERO registration number is CRD42021290542. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021290542.
Monitor for signs and symptoms of digoxin toxicity and clinical response. Adjust dose based on toxicity, efficacy, and blood levels.

Serum digoxin levels less than 0.5 ng/mL have been associated with diminished efficacy, while levels above 2 ng/mL have been associated with increased toxicity without increased benefit.

Interpret the serum digoxin concentration in the overall clinical context, and do not use an isolated measurement of serum digoxin concentration as the basis for increasing or decreasing the digoxin dose. Serum digoxin concentrations may be falsely elevated by endogenous digoxin-like substances [see Drug Interactions (7.4)].  If the assay is sensitive to these substances, consider obtaining a baseline digoxin level before starting digoxin and correct post-treatment values by the reported baseline level. 

Obtain serum digoxin concentrations just before the next scheduled digoxin dose or at least 6 hours after the last dose. The digoxin concentration is likely to be 10% to 25% lower when sampled right before the next dose (24 hours after dosing) compared to sampling 8 hours after dosing (using once-daily dosing). However, there will be only minor differences in digoxin concentrations using twice daily dosing whether sampling is done at 8 or 12 hours after a dose.
PURPOSE: A composition containing camphene is provided to effectively repel Scuticociliates causing mass mortality of fishes. CONSTITUTION: A Scuticociliates insecticide composition contains 0.00001-1.0 wt% of camphene as an active ingredient. The composition is a feed additive composition. The composition is manufactured in the form of a solution, suspension, emulsion, oil, or powder. A feed for fishes contains the composition. The feed contains Scuticociliates insecticidal additive. Camphene is isolated from pine trees and ginger by steam distillation, pressing, or solvent extraction.
In the main period, patients will begin Visit 1 receiving Adalimumab therapy at an initial dose (80 /0, 16 ml) on Visit 1, from Visit 2 Adalimumab therapy at a maintenance dose (40 /0, 8 ml) for up to Visit 9 of therapy. Each visit is conducted every two weeks ± 2 days. In additional period (from Visit 11 until Visit 28), eligible patients will continue to receive treatment after additional randomization (Adalimumab or Humira® (40 /0, 8 ml)) every 2 weeks until the end of a trial.
PURPOSE:To quickly start the operation by providing a related information retrieving means and retrieving inputted specifying information to prevent the malfunction for input. CONSTITUTION:A file system 41 consists of a picture output device 42 and a picture reproducing device 43. The output device 42 is provided with a specific information input means 44 by which information to specify the object of a picture is inputted, and inputted specifying information is outputted to a specifying information reception means 47 of the reproducing device 43 through a specifying information transmission means 46. In the reproducing device 43, a related information retrieving means 52 inputs specifying information from the reception means 47 to retrieve related information recorded in a related information recording means 53 and outputs it to a related information reception means 54. Further, the reception means 54 outputs related information to a related information reception means 49 of the output device 42. The reproducing device 43 receives the output of a synthesizing means 51, and the picture synthesized with related information is recorded by a recording means 56. Since specifying information is retrieved by the retrieving means 52 to prevent the malfunction for input in a series of these operations, endoscopic inspection or the like is quickly started.
<P>PROBLEM TO BE SOLVED: To provide an effective and safe anti-viral agent capable of being applied to fields such as medicines, cosmetics, foods, cleansers, daily necessaries, fibers, coatings, and resins, and to provide an anti-viral composition.  <P>SOLUTION: Provided are the antiviral agent comprising polyglycerol having a weight-average mol.wt. of 1,000 to 7,000; and the antiviral composition. The polyglycerol is preferably a branched polyglycerol. The preparations such as medicines, cosmetics, foods, cleansers, daily necessaries, fibers, coatings, and resins concretely include medicines such as gargles, nasal drops, and common cold medicines; cosmetics such as make-up creams, face-washing agents, body soaps, and hand soaps; hair cosmetics such as shampoos and rinses; foods such as candies, gummy candies, and drinking water; cleansers such as cleansers for vegetables or dishes, detergents for clothing, and softeners; daily necessaries such as masks, tissue paper, and gloves; fiber products such as fiber products for wiping up bodies or articles impregnated with liquids; coatings such as paints and lacquers; resins and the like.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A method of treating coronaviruses such as COVID 19, influenza and ARDS is provided. A copper chelator comprising tetrathiomolybdate is administered with a 5-lipoxygenase inhibitor, such as ethazine or zileuton. Baicalin, bufalin, quercetin, curcumin, NF- κB inhibitor, applied Therapeutics aldose reductase inhibitor AT-001, sulforaphane or fluvoxamine may be further medicaments. This is an interventional treatment of coronaviruses such as covd 19, ideally in the second phase of the disease, in the pulmonary phase, preferably prior to the excessive inflammatory phase, as a prophylactic therapy to reduce the need for a ventilator and to extend the survival of hospitalized patients. The goal of the combination of dual drug therapies is to prevent ARDS and other organ damage caused by covd 19 infection by targeting intravascular disease components. Oral and intravenous forms of tetrathiomolybdate in combination with other drugs in intravenous or inhaled form are designed to treat these diseases in advanced form.
This study was a split mouth design study included 32 side according to sample size calculation. Those sides were divided into 2 groups. Group 1divided into (group 1a: 8 sides with FTMPF, group 1b:8 sides control). Group 2(group 2 a: 8 sides with LLLT, group 2b: 8 sides control). Extraction of the first maxillary premolars followed by canine retraction in the extraction space with maximum anchorage were indicated. FTMPF was elevated from the mesial interdental papilla of maxillary canine to the mesial interdental papilla of second maxillary premolar. LLLT was applied at 3,7,14,28.56 days of retraction. During retraction study model for all patients were taken at 2ed, 6th, 14th,16th weeks and at the end of retraction (I1,I2,I3,I4,I5 or overall interval). 3D laser scanning and digital superimposition was done to measure the rate of canine retraction and anchorage loss.
The dry material of hydrogel substance for wound dressing made from synthetic and natural polymers contains gelatin and sodium alginate in the weight ratio 3:7 up to 7:3, whereby these two components create 100 wt. pts., and simultaneously contains 15-25 wt. pts of polyethylenglykol, 15-25 wt. pts of glycerine, 10-40 wt. pts of polyvinylalcohol nanofibres, 1 -3 wt. pts of natrium chloride, eventually further usual additives. A method of preparing the dry substance of hydrogel for wound dressing lies in t h a t initial aqueous polymeric solution of gelatin will be achieved during continuous stirring it in 180 - 220 wt. pts of water at the constant temperature 75 - 85°C, after dissolving whole volume of gelatin further components such as sodium alginate, polyethylene glycol, sodium chloride, glycerin and respectively sea buckthorn oil will be added to the initial aqueous polymeric solution of gelatin, whereupon stirring of this mixture will continue for 5 - 6 min at 250 - 350 rpm in order to a viscous hydrogel mass will be developed, then slowly a fraction of polyvinyl alcohol nanofibres will be added whereon the mixing speed of viscous mass will be reduced till 150 - 50 rpm, finally, the viscous mass will be poured into acrylic dishes of 25 mm diameter where it will be incubated at room temperature of 20 - 25°C until the whole volume of water is removed and the final dry material of hydrogel is achieved.
Participants will be asked to complete a set of questions during an outpatient clinic visit at St. Jude or Methodist Adult Comprehensive Sickle Cell Center. The questions ask about sickle cell disease knowledge and self-management skills, access to care, general adjustment, quality of life, and stress. These questions will take about 60 minutes to complete.

Participants will answer questionnaires on a password protected laptop or tablet using a computer program called Audio Computer-Assisted Self-Interviews (ACASI). The laptop or tablet will be kept by the study team. A study team member will be available during this time to address any technical issues or answer any questions. Participants will answer one of the questionnaires verbally, and the study team member will record responses from the questionnaire with paper and pen. Questionnaires given verbally will be audio-recorded and reviewed by the lead researcher or other study team member. The recordings will be destroyed immediately after review. No transcript or written record of the recordings will be made. Study members will meet five times with each participant during regularly-scheduled clinical visits over a two year period.

Two institutions will collaborate in the proposed project. St. Jude Children's Research Hospital (St. Jude) and the Methodist Comprehensive Sickle Cell Center will be the primary source of participants. Faculty from the University of Memphis, Department of Psychology, will be involved in methodological considerations and analyzing the data.
To develop an effective combined cognitive therapy (CT) plus drug treatment for patients with drug-resistant depression (DRD) (i.e., depression that is refractory to medication). To develop a manual for combined treatment for DRD that integrates three existing forms of CT (CT for depression, CT for personality disorders, and CT for anxiety disorders), and that specifies interventions for combining CT and medication when two therapists (psychotherapist and pharmacotherapist) provide the treatment. To obtain outpatient, randomized control, pilot data on the clinical value of the combined CT plus drug treatment, using the standard antidepressant desipramine (DMI), to obtain effect sizes and to determine if the treatment merits further investigation in a clinical trial. To develop a therapist adherence measure for the combined treatment.

Patients receive 1 of 2 treatments: CT plus DMI (n = 18) or DMI plus Clinical Management (n = 12). The first 6 of the 18 CT plus DMI patients are treated in a pre-pilot phase before randomization begins. All treatments continue for 6 months. The major assessment battery is administered at intake, 3 months, 6 months, and follow-up 6 months later. All treatments are closely monitored via audiotapes and supervision for purposes of developing and refining the CT plus drug treatment. The audiotapes are also used for development of the adherence measure. The primary outcome measures are Hamilton Rating Scale for Depression scores, Beck Depression Inventory scores, percent of patients who achieve clinical remission of symptoms, and percent showing attrition from treatment. Compliance with the treatment regimens is also a targeted and measured outcome variable.
Tacrolimus Capsules, USP are available containing the equivalent of 0.5 mg, 1 mg or 5 mg of anhydrous tacrolimus, USP.

  * The 0.5 mg capsules are hard-shell gelatin capsules with a light orange opaque cap and a gray opaque body filled with white to off-white powder. The capsules are axially printed with MYLANover 2045in black ink on both the cap and the body. 
  * The 1 mg capsules are hard-shell gelatin capsules with a light blue opaque cap and a gray opaque body filled with white to off-white powder. The capsules are axially printed with MYLANover 2046in black ink on both the cap and the body. 
  * The 5 mg capsules are hard-shell gelatin capsules with a rubine red opaque cap and a gray opaque body filled with white to off-white powder. The capsules are axially printed with MYLANover 2047in black ink on both the cap and the body.
Right ventricular (RV) pacing has long been the gold standard treatment for symptomatic brady arrhythmias. Right ventricular apical pacing has shown to cause electrical and mechanical desynchrony resulting in left ventricular (LV) dysfunction, and, in some cases, clinical heart failure together with other mechanical and arrhythmic complications. Hence, it was necessary to find a more physiologic method of pacing that ensures synchrony. His bundle pacing was first described in 2000, and is more recently adapted as a pacing method with less deleterious effects on the RV. However, lead dislodgement, high pacing thresholds, battery depletion, and difficulty identifying the exact location of His bundle were the most significant concerns related to this method. Subsequently, left bundle branch area pacing (LBB-AP), first described in 2017 by Huang et al, has emerged as safe alternative with excellent lead stability and capture threshold, and more ability to correct distal conduction disease as compared to His bundle pacing. Recent studies report promising mid-term outcome concerning left ventricular desynchrony. To the best of our knowledge, bi-ventricular activation was never studied in patients with LBB-AP.

Multiple tools have been used to assess biventricular (BiV) synchrony specially with chronic resynchronization therapy (CRT) including echocardiography and 12 lead ECG. Eschalier et al. found that epicardial noninvasive ECG mapping, was better at predicting clinical CRT response than QRS duration or the presence of LBBB. Activation patterns and timings with RV apical pacing, native LBBB, and BiV pacing have been well studied using this tool. With LBBP, however, these activation parameters have not yet been described.

This study aims to evaluate bi-ventricular activation in patients equipped with LBB-AP using non-invasive 3D mapping system in patients with or without baseline ventricular conduction disorder.
Systems, methods and devices for performing pulmonary procedures, and in particular treating lung disease. A flow control element includes a valve that prevents airflow in the inhalation direction but permits airflow in the exhalation direction. The flow control element is guided to and positioned at the site by a bronchoscope that is introduced into the patient's trachea and used to view the lungs during delivery of the flow control element. The valve may include one, two or more valve elements, and it may be collapsible for easier delivery. A source of vacuum or suction may be used to increase the amount of fluid withdrawn from the lung tissue. A device for measuring hollow structures, such as bronchioles, and a device for removing a previously-placed flow control element are disclosed as well.
Narrative Exposure Therapy (NET) Treatment: Treatment group consists of eligible individuals who are randomly assigned to receive NET treatment and are part of the study sample. Within each health center, treated individuals are randomly selected over several cohorts. In every cohort, the treatment group contained 6 individuals who received NET.
PROBLEM TO BE SOLVED: To obtain a skin cosmetic free from a sticky feeling in use, high in moisture retention effect, capable of maintaining the effect for many hours, by combining a water-soluble polyhydric alcohol excellent in water retention and water vapor absorption with a specific compound. SOLUTION: This skin cosmetic comprises at least one or more of α, αtrehalose-6,6' di-fatty acid esters and at least one or more of water-soluble polyhydric alcohols. The α, α-trehalose-6,6' di-fatty acid ester is mixed with water and the polyhydric alcohol to form a liquid crystal. The liquid crystal has characteristics of highly associating and configurating an amphiphatic substance and retaining a large amount of water in the structure. For example, glycerol, diglycerol, propylene glycol, etc., may be cited as the water-soluble polyhydric alcohol. The amount of the α, α-trehalose-6,6' di-fatty acid ester mixed is about 0.0001-20wt.% based on the skin cosmetic. The blending ratio of the ester to the alcohol is approximately 1:1,000 to 1:1.
NITROUS OXIDE USP

UN1070

DO NOT REMOVE THIS LABEL.

Rx only. WARNING: Administration of Nitrous Oxide may be hazardous or contraindicated. For use only by or under the supervision of a licensed practitioner who is experienced in the use and administration of Nitrous Oxide and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications and side effects, and the precautions to be taken. DANGER: MAY CAUSE OR INTENSIFY FIRE; OXIDIZER. CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED. MAY CAUSE DROWSINESS OR DIZZINESS. MAY DISPLACE OXYGEN AND CAUSE RAPID SUFFOCATION. MAY CAUSE FROSTBITE. Do not handle until all safety precautions have been read and understood. Keep and store away from clothing and other combustible materials. Keep valves and fittings free from grease and oil. Avoid breathing gas. Do not get in eyes, on skin, or on clothing. Use and store only outdoors or in a well-ventilated place. Wear protective gloves, protective clothing, and either eye or face protection. In case of fire: Stop leak if safe to do so. Store locked up. Dispose of contents/container in accordance with container supplier/owner instructions. Use a back flow preventive device in the piping. Close valve after each use and when empty. Use only with equipment rated for cylinder pressure. Do not open valve until connected to equipment prepared for use. Use only equipment of compatible materials of construction. Open valve slowly. Use only with equipment cleaned for oxygen service. Protect from sunlight when ambient temperature exceeds 52 C (125 F). Read and follow the Safety Data Sheet (SDS) before use. FIRST AID: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call POISION CENTER or doctor/physician if you feel unwell. IF ON SKIN: Thaw frosted parts with lukewarm water. Do not rub affected area. Get immediate medical advice/attention. CAS: 10024-97-2

WARNING: This product can expose you to chemicals including Nitrous Oxide, which is known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

DISTRIBUTED BY:

WELSCO.

9006 CRYSTAL HILL ROAD

NORTH LITTLE ROCK, AR 72113 501-771-1204 

Revised: 12/2024

Document Id: 284cadf1-deb8-4f3d-e063-6394a90ab122

34391-3

Set id: e804b2a1-2b96-34a4-e053-2995a90aa9b4

Version: 4

Effective Time: 20241202

WELSCO, INC.
Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.